The present invention provides methods and compositions for treating cancer patients, and in particular, breast cancer patients, who are responsive to antiprogestin therapy, or who may be induced to be responsive to an antiprogestin therapy through the administration of a demethylation agent, optionally together with an HDAC inhibitor. Further, the present invention relates to a method of screening cancer patients using BCL-XL as a marker protein.